Oregon did something genuinely historic when it voted to create the first state-regulated psilocybin program in the country. For anyone interested in psychedelics, plant medicine, or the slow drift of mushrooms out of the underground and into licensed spaces, it was a moment worth marking. So you'd assume the venture capital crowd — the same people pouring tens of millions into psychedelic startups — would be lining up at the border with checkbooks open.

They're not. Several of the most active investors in the psychedelics space have quietly made it clear they're skipping Oregon, at least for now. Their reasoning is worth understanding, because it tells you something useful about where this whole industry is heading — and what it might mean for the kind of retreat experience you can actually book in the years ahead.

What Oregon Actually Built

Measure 109 created a framework where adults can take psilocybin under the supervision of a licensed facilitator at a licensed service center. It's not medical. It's not recreational. It's a third thing — call it supported use — and it sits inside a single state while psilocybin remains a Schedule I substance at the federal level. That last detail is doing a lot of heavy lifting in this story.

The companies preparing to operate in Oregon are mostly retreat centers, training programs for facilitators, and small clinic-style operations. Some are familiar names in the psychedelic retreat world — outfits that have spent years running ceremonies in places like the Netherlands or Jamaica and now want a foothold inside the United States. On paper, it looks like the beginning of a real market.

Why the Money Is Saying No (Politely)

Talk to people running psychedelic-focused venture funds and a few specific objections come up again and again. None of them are about whether psilocybin works. They're about whether a business built around it can make money under the rules as written.

The first issue is taxes. Because psilocybin is federally illegal, businesses handling it get hit by the same IRS provision — Section 280E — that has been making life miserable for cannabis operators for years. In plain English: you can't deduct normal business expenses like rent, payroll, or marketing the way an ordinary company can. Your effective tax rate balloons. Margins that already look thin get sliced even thinner.

The second issue is the math of a single session. A ketamine clinic — currently the closest legal comparison in the US — can move a patient through treatment in roughly an hour or two. A psilocybin session runs significantly longer; six hours is a reasonable baseline once you add preparation and the come-down. That's one room, one facilitator (sometimes two), one client, for most of a working day. Even at premium pricing, the unit economics get tight fast.

The third issue is scale. Venture capital looks for businesses that can grow ten or a hundred times larger with an injection of cash. A retreat center on a 124-acre property in southern Oregon is a beautiful thing. It is not, in the VC sense, scalable. You can't ship it. You can't 100x it. You can open a second one, eventually, and that's about it.

The Other Path Investors Are Betting On Instead

The money is mostly flowing somewhere else: toward biotech companies running clinical trials on psilocybin, MDMA, and related compounds, hoping to get them approved as prescription medicines through the FDA. If that approval comes — and several late-stage trials suggest it might, for conditions like treatment-resistant depression and PTSD — those companies suddenly have a federally legal product, insurance reimbursement, and a defensible patent position.

That's a very different business than running ceremonies in a wooden lodge with a facilitator who sings to you for six hours. It's pharmaceutical psychedelics. It's also where most of the venture capital has gone for the past several years, and it explains a lot about the public conversation around psychedelic healing — what gets covered, what gets funded, what gets framed as legitimate.

What This Means If You're Considering a Retreat

Here's where it gets interesting for the person actually researching whether to sit in a ceremony. The VC cold shoulder toward Oregon isn't necessarily bad news. In some ways it might be the best thing that could happen to the experience itself.

When venture money flows in, it brings expectations. Growth targets. Standardized protocols. Pressure to move clients through faster. The retreat world has spent decades being shaped by tradition, by individual facilitators, by lineage, by the slow accumulation of practice. The places that resist quick scaling are often the ones doing the most careful work.

That said, there are some practical things worth knowing if you're weighing Oregon as a destination versus going to an established ayahuasca or psilocybin retreat abroad:

• Cost will likely be high. Those tax burdens and long session times get passed along. Early estimates for a single Oregon psilocybin session have ranged anywhere from $1,000 to several thousand dollars, before you add lodging or any kind of multi-day program.
• The container is different from a traditional ceremony. Oregon's framework is built around licensed facilitators and service centers, not curanderos and maestros. Some people prefer that clarity. Others find it missing the depth and ritual context that draws them to plant medicine in the first place.
• Federal law still matters. If you work in a regulated profession, hold a security clearance, or travel internationally for work, the federal-illegality piece isn't theoretical. Worth thinking through before you book.
• Group retreats overseas are often less expensive. A week-long ayahuasca retreat in Peru or a psilocybin retreat in Jamaica or the Netherlands frequently costs less than a single Oregon session, accommodation included.

Ayahuasca, Master Plants, and the Bigger Picture for Plant Medicine

Most of this VC drama is centered on psilocybin specifically, because that's what Oregon legalized. But it sits inside a bigger conversation about plant medicine as a whole. Ayahuasca, San Pedro, iboga, peyote — what indigenous traditions often call master plants — operate in a legal and cultural space that's even more complicated than mushrooms in Oregon. They're not on the table for state-level legalization in the US anytime soon, and the established retreats for these medicines are almost entirely outside the country.

For people seeking help with addiction, depression, or the kind of stuck patterns that talk therapy hasn't budged, the choice often comes down to: wait for a clinical pipeline that may or may not deliver a relevant treatment in five years, try the new Oregon model when it opens up, or travel to an established retreat tradition that has been doing this work for decades or centuries. None of these is automatically the right answer. They're different doors into different rooms.

What's clear is that the underground-to-legal transition is messier than the headlines suggest. The investors backing away from Oregon aren't doing it because they think psychedelics don't work. They're doing it because they think the business model is hard. Those are different things, and confusing them leads to bad decisions on both ends — investors missing real opportunities, and seekers assuming that what gets the most funding must be the best path to healing.

How to Choose Where to Sit

If you're somewhere in that 22-to-60 bracket of adults quietly looking into this for real reasons — addiction in the family, depression that won't lift, grief that's gone on too long — the most useful thing you can do is ignore the industry noise and ask basic questions of any program you're considering:

1. Who is the lead facilitator, what's their training, and how long have they been doing this work?
2. What's the screening process? A good retreat will turn people away — for medications, medical conditions, or psychological reasons. If they take anyone with a credit card, that's a flag.
3. What does preparation look like in the weeks before you arrive, and what does integration support look like after? The ceremony is the smallest part of the experience.
4. What's the group size, and what's the facilitator-to-participant ratio during ceremony?
5. What happens if something goes wrong — medically or psychologically — at three in the morning?

You won't find these answers in a glossy brochure. You'll find them in long phone calls, honest references, and the willingness of a retreat to talk about hard cases instead of dream testimonials.

The legal landscape will keep shifting. Oregon will figure out its market, or it won't. Colorado, which passed its own measure shortly after, will run its own experiment. Federal approval for psilocybin therapy could land within a few years. None of that changes the basic question for the person reading this: is plant medicine the right next step for you, and if so, with whom, where, and when?

For readers who want to explore this further with a clearer view of the options, a curated range of ayahuasca and psilocybin retreats can be browsed on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and the right container is worth waiting for.